The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use of antiretroviral therapy (ART) superior to deferral of ART until…
Compulsory drug detention centers (CDDCs) are common throughout Asia. However, medical treatments for substance use disorders, such as opioid agonist treatment (OAT), are generally unavailable in these settings. In this report, we compare the effectiveness of CDDCs with voluntary drug…
First-line antiretroviral regimens are safe, effective and easily administered (one pill taken once daily). Even so, the annual failure rate is around 10-15% of treated patients. Second-line regimens have a number of limitations, disproportionately impacting resource-limited settings. Ideally choice of…
TREAT Asia has pioneered the first database to assess the natural history of HIV disease in treated and untreated patients throughout Asia and the Pacific. In an unprecedented regional collaboration on HIV research, 17 clinical sites in Cambodia, China, Hong…
The use of highly active antiretroviral therapy (HAART) has led to dramatic reductions in morbidity and mortality in HIV patients. However, tuberculosis (TB) remains a common opportunistic infections and a major cause of death among patients with HIV, especially in…
Antiretroviral therapy is complicated by drug interactions and contraindications. Novel regimens are needed. This open label study randomly assigned treatment-naive, human immunodeficiency virus (HIV)—infected subjects to receive tenofovir-emtricitabine with efavirenz (Arm I), with ritonavir-boosted atazanavir (Arm II), or with zidovudine/abacavir…
WHO-recommended second-line antiretroviral therapy (ART) of a pharmacologically enhanced (boosted) protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compromised by resistance. Results of the 96 week SECOND-LINE randomised trial showed that NtRTI-sparing ART with ritonavir-boosted lopinavir…
“ENCORE (for Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy) was a program originally designed to examine the safety and efficacy of lower doses of important antiretroviral drugs (ART). This was intended to allow donors, governments and non-government organisations…
The Second National Consultation on the Use of Antiretroviral Pre-exposure Prophylaxis (PrEP) to Prevent HIV Acquisition was held in Kuala Lumpur, Malaysia, on 4 June 2018. The consultation was convened by the Centre of Excellence for Research in AIDS (CERiA)…
Project HARAPAN was a 2×2 randomized, controlled trial of a prison-based, pre-release methadone program and an evidence-based behavioral intervention (HHRP) for HIV-infected, opioid dependent prisoners in Malaysia. Participants were randomized to one of four study arms: methadone only; HHRP only;…
